Gibson Dunn advised Arrowhead Pharmaceuticals on asset purchase agreement with Sanofi and Visirna Therapeutics
Global law firm Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms of the agreement, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China.
The Gibson Dunn team was led by Karen Alexandra Spindler (Partner, San Francisco), the corporate team includes Jin Hee Kim (Partner, New York) and associates Paul Rafla (Associate, New York) and Sonari Chidi (Associate, Los Angeles). Partners Pamela Lawrence Endreny (Partner, New York) and Benjamin Rapp (Partner, Munich, Frankfurt) and associate Ryan Rott (Associate, New York) advised on tax. Cassandra Gaedt-Sheckter (Partner, Palo Alto) and Courtney Wang (Associate, San Francisco) advised on data privacy. John Partridge (Partner, Denver) and Ning Ning (Of Counsel, Hong Kong) advised on compliance.
Click to know more about Gibson Dunn
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.